On September 28, 2016, Aegerion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it received marketing authorization approval from the Japanese Ministry of Health, Labor and Welfare for JUXTAPID® (lomitapide) capsules for the treatment of patients with homozygous familial hypercholesterolemia in Japan. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
On September 30, 2016, the Company entered into a sixth amendment (the “Sixth Amendment”) to the forbearance agreement dated November 9, 2015, as amended on December 7, 2015, January 7, 2016, February 26, 2016, June 8, 2016 and June 14, 2016, between the Company and Silicon Valley Bank (“SVB”) to extend the existing forbearance period under the Loan and Security Agreement, dated as of March 28, 2012, between the Company and SVB (as amended, supplemented or otherwise modified) through November 30, 2016.
The foregoing summary of certain terms of the Sixth Amendment is qualified in its entirety by the terms of the Sixth Amendment, which will be filed as an exhibit to the Company’s Form 10-Q for the fiscal quarter ended September 30, 2016.